PAP
MLTX icon

Persistent Asset Partners’s MoonLake Immunotherapeutics MLTX Stock Holding History

Persistent Asset Partners’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,523
Closed -$112K – 422
2025
Q4 		$112K Buy
+8,523
New +$101K 0.05% 261

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Persistent Asset Partners's MLTX Position: Q1 2026 in Review

Persistent Asset Partners sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2026, closing a stake of 8,523 shares — an estimated $112K sold.

Persistent Asset Partners first reported a position in MLTX in Q4 2025 and held it in 1 quarter. The position peaked at $112K in Q4 2025. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

  • Persistent Asset Partners reported no remaining MoonLake Immunotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 8,523 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $112K.
  • Persistent Asset Partners first reported a position in MoonLake Immunotherapeutics in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's MoonLake Immunotherapeutics position peaked at $112K in Q4 2025.
  • 147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.